We provide a strong voice and concerted effort to promote the social, economic and environmental well being of people living with arthritis. We communicate with all levels of government to make positive changes to health policies. We maintain formal and informal networks, initiate or participate in committees and partnerships with other organizations to better enable us to negotiate on behalf of people living with arthritis - and we talk to our neighbors.
Our operations depend on support from many sources that include organizations, industry, government and individuals who believe in what we do. We thank you all. Our funding policy is found here.
Sources of grants and support received by CAPA (including in-kind support) in the last two years include: AbbVie Canada, Alliance for Safe Biologic Medicines, Amgen Canada, Arthritis Alliance of Canada, The Arthritis Society, Best Medicines Coalition, CADTH, Canadian Rheumatology Association, Eli Lilly Canada, European League Against Rheumatism, Janssen Canada, Manulife, Novartis Canada, Ontario Rheumatology Association, Pfizer Canada (including Pfizer Hospira), Purdue Pharma Canada, Sanofi, and UCB Pharma.
In addition to the organizations listed above, CAPA has also received support in the past from: Canadian Institutes of Health Research, Hoffman-La Roche, Innovative Medicines Canada (formerly Rx&D), Schering Canada, Scleroderma Society, and STA Communications.